Table 2.
Top 100 papers in gallbladder cancer management.
| Rank | Paper | TC |
|---|---|---|
| 1 | Valle J et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine. 2010; 362:1273–1281. | 1822 |
| 2 | Schnitzbauer AA et al. Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings. Annals of Surgery. 2012; 255:405–414. | 749 |
| 3 | Lazcano-Ponce EC et al. Epidemiology and molecular pathology of gallbladder cancer. Ca-a Cancer Journal for Clinicians. 2001; 51:349–364. | 538 |
| 4 | Nakamura H et al. Genomic spectra of biliary tract cancer. Nature Genetics. 2015; 47:1003-+. | 509 |
| 5 | Hundal R et al. Gallbladder cancer: epidemiology and outcome. Clinical Epidemiology. 2014; 6:99–109. | 490 |
| 6 | Randi G et al. Gallbladder cancer worldwide: Geographical distribution and risk factors. International Journal of Cancer. 2006; 118:1591–1602. | 486 |
| 7 | Stinton LM et al. Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer. Gut and Liver. 2012; 6:172–187. | 480 |
| 8 | Misra S et al. Carcinoma of the gallbladder. Lancet Oncology. 2003; 4:167–176. | 476 |
| 9 | Takada T et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95:1685–1695. | 431 |
| 10 | Okusaka T et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer. 2010; 103:469–474. | 401 |
| 11 | Horgan AM et al. Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology. 2012; 30:1934–1940. | 394 |
| 12 | Nagino M et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer - Surgical outcome and long-term follow-up. Annals of Surgery. 2006; 243:364–372. | 361 |
| 13 | Eckel F et al. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. British Journal of Cancer. 2007; 96:896–902. | 355 |
| 14 | Shibata T et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology. 2008; 135:1358–1368. | 344 |
| 15 | Benson AB et al. Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Network. 2009; 7:350–391. | 342 |
| 16 | Nduka CC et al. Abdominal-Wall Metastases Following Laparoscopy. British Journal of Surgery. 1994; 81:648–652. | 339 |
| 17 | Jarnagin WR et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma - Implications for adjuvant therapeutic strategies. Cancer. 2003; 98:1689–1700. | 308 |
| 18 | Bartlett DL et al. Long-term results after resection for gallbladder cancer - Implications for staging and management. Annals of Surgery. 1996; 224:639–646. | 306 |
| 19 | Henson DE et al. Carcinoma of the Gallbladder - Histologic Types, Stage of Disease, Grade, and Survival Rates. Cancer. 1992; 70:1493–1497. | 305 |
| 20 | Primrose JN et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicentre, phase 3 study. Lancet Oncology. 2019; 20:663–673. | 302 |
| 21 | Fong Y et al. Gallbladder cancer: Comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Annals of Surgery. 2000; 232:557–566. | 297 |
| 22 | Lee J et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary tract cancer: a multicentre, open-label, randomized, phase 3 study. Lancet Oncology. 2012; 13:181–188. | 294 |
| 23 | Cubertafond P et al. Surgical Treatment of 724 Carcinomas of the Gallbladder - Results of the French-Surgical-Association Survey. Annals of Surgery. 1994; 219:275–280. | 275 |
| 24 | De Palma GD et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointestinal Endoscopy. 2001; 53:547–553. | 269 |
| 25 | Malka D et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary tract cancer (BINGO): a randomized, open-label, non-comparative phase 2 trial. Lancet Oncology. 2014; 15:819–828. | 243 |
| 26 | Knox JJ et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. Journal of Clinical Oncology. 2005; 23:2332–2338. | 242 |
| 27 | Nimura Y et al. Hepatopancreatoduodenectomy for Advanced-Carcinoma of the Biliary Tract. Hepato-Gastroenterology. 1991; 38:170–175. | 242 |
| 28 | Ben-Josef E et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. Journal of Clinical Oncology. 2005; 23:8739–8747. | 236 |
| 29 | Reilly WT et al. Wound recurrence following conventional treatment of colorectal cancer - A rare but perhaps underestimated problem. Diseases of the Colon & Rectum. 1996; 39:200–207. | 233 |
| 30 | Paolucci V et al. Tumor seeding following laparoscopy: International survey. World Journal of Surgery. 1999; 23:989–997. | 231 |
| 31 | Ogura Y et al. Radical Operations for Carcinoma of the Gallbladder - Present Status in Japan. World Journal of Surgery. 1991; 15:337–343. | 227 |
| 32 | Anderson CD et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. Journal of Gastrointestinal Surgery. 2004; 8:90–97. | 226 |
| 33 | Valle JW et al. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discovery. 2017; 7:943–962. | 219 |
| 34 | Duffy A et al. Gallbladder Cancer (GBC): 10-Year Experience at Memorial Sloan–Kettering Cancer Center (MSKCC). Journal of Surgical Oncology. 2008; 98:485–489. | 219 |
| 35 | Zhu AX et al. Current Management of Gallbladder Carcinoma. Oncologist. 2010; 15:168–181. | 206 |
| 36 | Valle JW et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomized trials. Annals of Oncology. 2014; 25:391–398. | 199 |
| 37 | Weber SM et al. Intrahepatic Cholangiocarcinoma: expert consensus statement. Hpb. 2015; 17:669–680. | 191 |
| 38 | Zatonski WA et al. Epidemiologic aspects of gallbladder cancer: A case–control study of the SEARCH Program of the International Agency for Research on Cancer. Jnci-Journal of the National Cancer Institute. 1997; 89:1132–1138. | 191 |
| 39 | Aloia TA et al. Gallbladder Cancer: expert consensus statement. Hpb. 2015; 17:681–690. | 190 |
| 40 | Cuschieri A. Whither Minimal Access Surgery - Tribulations and Expectations. American Journal of Surgery. 1995; 169:9–19. | 190 |
| 41 | Petrowsky H et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. Journal of Hepatology. 2006; 45:43–50. | 189 |
| 42 | Nakazawa K et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. Journal of Pathology. 2005; 206:356–365. | 187 |
| 43 | Levy AD et al. Gallbladder carcinoma: Radiologic-pathologic correlation. Radiographics. 2001; 21:295–314. | 187 |
| 44 | Bergquist A et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case–control study. Hepatology. 1998; 27:311–316. | 185 |
| 45 | Valle JW et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumors: a multicentre randomized phase II study - The UK ABC-01 Study. British Journal of Cancer. 2009; 101:621–627. | 184 |
| 46 | Sharma A et al. Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study. Journal of Clinical Oncology. 2010; 28:4581–4586. | 181 |
| 47 | Hezel AF et al. Systemic therapy for biliary tract cancers. Oncologist. 2008; 13:415–423. | 178 |
| 48 | Shirai Y et al. Radical Surgery for Gallbladder Carcinoma - Long-Term Results. Annals of Surgery. 1992; 216:565–568. | 178 |
| 49 | Pawlik TM et al. Incidence of finding residual disease for incidental gallbladder carcinoma: Implications for re-resection. Journal of Gastrointestinal Surgery. 2007; 11:1478–1486. | 171 |
| 50 | Lubner SJ et al. Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study. Journal of Clinical Oncology. 2010; 28:3491–3497. | 170 |
| 51 | Mansour JC et al. Hilar Cholangiocarcinoma: expert consensus statement. Hpb. 2015; 17:691–699. | 169 |
| 52 | Randi G et al. Epidemiology of biliary tract cancers: an update. Annals of Oncology. 2009; 20:146–159. | 168 |
| 53 | Kondo S et al. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. British Journal of Surgery. 2000; 87:418–422. | 167 |
| 54 | Johnstone PAS et al. Port site recurrences after laparoscopic and thoracoscopic procedures in malignancy. Journal of Clinical Oncology. 1996; 14:1950–1956. | 167 |
| 55 | Ben-Josef E et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of Clinical Oncology. 2015; 33:2617-U2657. | 166 |
| 56 | Dixon E et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer - A 12-year study at a North American center. Annals of Surgery. 2005; 241:385–394. | 166 |
| 57 | Mager DL. Bacteria and cancer: cause, coincidence or cure? A review. Journal of Translational Medicine. 2006; 4. | 163 |
| 58 | Weber SM et al. Staging laparoscopy in patients with extrahepatic biliary carcinoma - Analysis of 100 patients. Annals of Surgery. 2002; 235:392–399. | 160 |
| 59 | Shimada H et al. The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer. 1997; 79:892–899. | 157 |
| 60 | Corvera CU et al. F-18-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. Journal of the American College of Surgeons. 2008; 206:57–65. | 157 |
| 61 | Shih SP et al. Gallbladder cancer: The role of laparoscopy and radical resection. Annals of Surgery. 2007; 245:893–901. | 156 |
| 62 | Cheng JLS et al. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointestinal Endoscopy. 2002; 56:33–39. | 156 |
| 63 | Razumilava N et al. Cancer Surveillance in Patients With Primary Sclerosing Cholangitis. Hepatology. 2011; 54:1842–1852. | 155 |
| 64 | Donohue JH et al. The National Cancer Data Base Report on Carcinoma of the Gallbladder, 1989–1995. Cancer. 1998; 83:2618–2628. | 154 |
| 65 | Hezel AF et al. Genetics of Biliary Tract Cancers and Emerging Targeted Therapies. Journal of Clinical Oncology. 2010; 28:3531–3540. | 153 |
| 66 | Tsukada K et al. Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage. Surgery. 1996; 120:816–821. | 153 |
| 67 | Fong YM et al. Gallbladder Cancer Discovered during Laparoscopic Surgery - Potential for Iatrogenic Tumor Dissemination. Archives of Surgery. 1993; 128:1054–1056. | 152 |
| 68 | Benoist S et al. Long-term results after curative resection for carcinoma of the gallbladder. American Journal of Surgery. 1998; 175:118–122. | 151 |
| 69 | Attili AF et al. The Natural-History of Gallstones - the Grepco Experience. Hepatology. 1995; 21:656–660. | 151 |
| 70 | Cirocco WC et al. Abdominal-Wall Recurrence after Laparoscopic Colectomy for Colon-Cancer. Surgery. 1994; 116:842–846. | 151 |
| 71 | Patt YZ et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004; 101:578–586. | 150 |
| 72 | Clair DG et al. Rapid Development of Umbilical Metastases after Laparoscopic Cholecystectomy for Unsuspected Gallbladder Carcinoma. Surgery. 1993; 113:355–358. | 150 |
| 73 | Drouard F et al. Cutaneous Seeding of Gallbladder Cancer after Laparoscopic Cholecystectomy. New England Journal of Medicine. ;325:1316–1316. |
149 |
| 74 | Murakami Y et al. Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. Annals of Surgical Oncology. 2011; 18:651–658. | 145 |
| 75 | Kondo S et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. Journal of Hepato-Biliary-Pancreatic Surgery. 2008; 15:41–54. | 145 |
| 76 | Overby DW et al. SAGES guidelines for the clinical application of laparoscopic biliary tract surgery. Surgical Endoscopy and Other Interventional Techniques. 2010; 24:2368–2386. | 144 |
| 77 | Sharma A et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update. World Journal of Gastroenterology. 2017; 23:3978–3998. | 142 |
| 78 | Reid KM et al. Diagnosis and surgical management of gallbladder cancer: A review. Journal of Gastrointestinal Surgery. 2007; 11:671–681. | 142 |
| 79 | Strom BL et al. Risk Factors for Gallbladder Cancer - an International Collaborative Case - Control Study. Cancer. 1995; 76:1747–1756. | 141 |
| 80 | Miller G et al. Gallbladder carcinoma. Ejso. 2008; 34:306–312. | 139 |
| 81 | Schaeff B et al. Port site recurrences after laparoscopic surgery - A review. Digestive Surgery. 1998; 15:124–134. | 139 |
| 82 | Naitoh I et al. Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. Journal of Gastroenterology and Hepatology. 2009; 24:552–557. | 133 |
| 83 | Miyakawa S et al. Biliary tract cancer treatment: 5584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. Journal of Hepato-Biliary-Pancreatic Surgery. 2009; 16:1–7. | 133 |
| 84 | Ransohoff DF et al. Treatment of Gallstones. Annals of Internal Medicine. 1993; 119:606–619. | 132 |
| 85 | Fernandez E et al. Hormone replacement therapy and cancer risk: A systematic analysis from a network of case–control studies. International Journal of Cancer. 2003; 105:408–412. | 130 |
| 86 | Madoff DC et al. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for major liver resection for hepatobiliary malignancy: Safety and effectiveness - Study in 26 patients. Radiology. 2003; 227:251–260. | 130 |
| 87 | Ito H et al. Accurate Staging for Gallbladder Cancer Implications for Surgical Therapy and Pathological Assessment. Annals of Surgery. 2011; 254:320–325. | 129 |
| 88 | Tsukada K et al. Lymph node spread from carcinoma of the gallbladder. Cancer. 1997; 80:661–667. | 129 |
| 89 | Javle M et al. HER2/neu-directed therapy for biliary tract cancer. Journal of Hematology & Oncology. 2015; 8. | 128 |
| 90 | D'Angelica M et al. Analysis of the Extent of Resection for Adenocarcinoma of the Gallbladder. Annals of Surgical Oncology. 2009; 16:806–816. | 128 |
| 91 | Hawkins WG et al. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Annals of Surgical Oncology. 2004; 11:310–315. | 128 |
| 92 | Wang SJ et al. Nomogram for Predicting the Benefit of Adjuvant Chemoradiotherapy for Resected Gallbladder Cancer. Journal of Clinical Oncology. 2011; 29:4627–4632. | 125 |
| 93 | DeWitt J et al. EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointestinal Endoscopy. 2006; 64:325–333. | 125 |
| 94 | Wakai T et al. Early gallbladder carcinoma does not warrant radical resection. British Journal of Surgery. 2001; 88:675–678. | 125 |
| 95 | Liu TY et al. Baicalein Inhibits Progression of Gallbladder Cancer Cells by Downregulating ZFX. Plos One. 2015; 10. | 124 |
| 96 | Kim JY et al. Clinical role of (18)F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: A prospective study compared with conventional imaging. American Journal of Gastroenterology. 2008; 103:1145–1151. | 124 |
| 97 | Leone F et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clinical Cancer Research. 2006; 12:1680–1685. | 124 |
| 98 | Chijiiwa K et al. Surgical treatment of patients with T2 gallbladder carcinoma invading the subserosal layer. Journal of the American College of Surgeons. 2001; 192:600–607. | 124 |
| 99 | Kanthan R et al. Gallbladder Cancer in the 21st Century. Journal of Oncology. 2015; 2015. | 123 |
| 100 | Gourgiotis S et al. Gallbladder cancer. American Journal of Surgery. 2008; 196:252–264. | 123 |
TC, Total citations.